Novo Nordisk NVO, +0.01% on Monday announced a partnership with Valo Health Inc., a technology company specializing in AI-powered drug discovery and development, to focus on new cardiometabolic drug programs. The Danish pharmaceutical giant, maker of Ozempic and Wegovy, has also licensed three preclinical cardiovascular drug discovery programs from Valo, the companies said in a release.
7 billion, plus research and development funding and potential royalty payments, the companies said. “Artificial intelligence and machine learning hold the promise to positively impact drug discovery and development, in particular enabling our vision of leveraging human datasets early in the process, which should lead to a better understanding of target biology,” Novo Nordisk chief scientific officer Marcus Schindler said in a statement. Novo’s American depositary receipts fell 0.
Ai Ai Latest News, Ai Ai Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: IntEngineering - 🏆 287. / 63 Read more »